Toward the first class of suicide inhibitors of kallikreins involved in skin diseases

Journal of Medicinal Chemistry

Volumn 58, Issue 2, 2015, Pages 598-612

  Tan, Xiao ^a,b   Soualmia, Feryel ^a,b   Furio, Laetitia ^c   Renard, Jean François ^d   Kempen, Isabelle ^d   Qin, Lixian ^a,b   Pagano, Maurice ^a,b   Pirotte, Bernard ^d   El Amri, Chahrazade ^a,b   Hovnanian, Alain ^c   Reboud Ravaux, Michèle ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b Groupe Enzymologie Moléculaire et Fonctionnelle   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

(3 HALO)PHENYL 6 (HYDROXYMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 1 NAPHTHYL 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 2 CARBOXYPHENYL 6 (CHLOROMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 2 METHOXYCARBONYLPHENYL 6 (CHLOROMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 2 NAPHTHYL 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 BROMOPHENYL 6 (BROMOMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 CARBAMOYLPHENYL 6 (CHLOROMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 CARBOXYPHENYL 6 (CHLOROMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 CHLOROPHENYL 6 (BROMOMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 CHLOROPHENYL 6 (FLUOROMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 CHLOROPHENYL 6 (HYDROXYMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 FLUOROPHENYL 6 (BROMOMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 FLUOROPHENYL 6 (HYDROXYMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 3 METHOXYCARBONYLPHENYL 6 (CHLOROMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; 4 METHOXYCARBONYLPHENYL 6 (CHLOROMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; CARBOXYLIC ACID DERIVATIVE; COUMARIN DERIVATIVE; DI 3 BROMOPHENYL MALONATE; ISOQUINOL 1 YL 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; KALLIKREIN; KALLIKREIN 14; KALLIKREIN 5; KALLIKREIN INHIBITOR; MATRIPTASE; PHENYL 6 (BROMOMETHYL) 2 OXO 2H1 BENZOPYRAN 3 CARBOXYLATE; PHENYL 6 (HYDROXYMETHYL) 2 OXO 2H 1 BENZOPYRAN 3 CARBOXYLATE; STRATUM CORNEUM CHYMOTRYPTIC ENZYME; UNCLASSIFIED DRUG; KLK5 PROTEIN, HUMAN; KLK7 PROTEIN, HUMAN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; KERATINOCYTE; MOLECULAR MODEL; MOUSE; NONHUMAN; PH; PROTEIN DEGRADATION; SKIN DISEASE; STRUCTURE ACTIVITY RELATION; SUICIDE SUBSTRATE; ZYMOGRAPHY; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; PHYSIOLOGY; SKIN DISEASES;

COUMARINS; HUMANS; KALLIKREINS; SERINE ENDOPEPTIDASES; SERINE PROTEINASE INHIBITORS; SKIN DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84921478875     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500988d     Document Type: Article

References (53)

1. Borgono, C. A.; Michael, I. P.; Komatsu, N.; Jayakumar, A.; Kapadia, R.; Clayman, G. L.; Sotiropoulou, G.; Diamandis, E. P. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation J. Biol. Chem. 2007, 282, 3640-3652
2. de Veer, S. J.; Furio, L.; Harris, J. M.; Hovnanian, A. Proteases: common culprits in human skin disorders Trends Mol. Med. 2013, 20, 166-178
3. Hovnanian, A. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition Cell. Tissue Res. 2013, 351, 289-300
4. Bitoun, E.; Micheloni, A.; Lamant, L.; Bonnart, C.; Tartaglia-Polcini, A.; Cobbold, C.; Al Saati, T.; Mariotti, F.; Mazereeuw-Hautier, J.; Boralevi, F.; Hohl, D.; Harper, J.; Bodemer, C.; DAlessio, M.; Hovnanian, A. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome Hum. Mol. Genet. 2003, 12, 2417-2430
5. Brattsand, M.; Stefansson, K.; Lundh, C.; Haasum, Y.; Egelrud, T. A proteolytic cascade of kallikreins in the stratum corneum J. Invest. Dermatol. 2005, 124, 198-203
6. Sales, K. U.; Masedunskas, A.; Bey, A. L.; Rasmussen, A. L.; Weigert, R.; List, K.; Szabo, R.; Overbeek, P. A.; Bugge, T. H. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome Nat. Genet. 2010, 42, 676-683
7. Miyai, M.; Matsumoto, Y.; Yamanishi, H.; Yamamoto-Tanaka, M.; Tsuboi, R.; Hibino, T. Keratinocyte-specific mesotrypsin contributes to the desquamation process via kallikrein activation and LEKTI degradation J. Invest. Dermatol. 2014, 134, 1665-1674
8. Meyer-Hoffert, U. Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases Arch. Immunol. Ther. Exp. (Warsz) 2009, 57, 345-354
9. Schultz, S.; Saalbach, A.; Heiker, J. T.; Meier, R.; Zellmann, T.; Simon, J. C.; Beck-Sickinger, A. G. Proteolytic activation of prochemerin by kallikrein 7 breaks an ionic linkage and results in C-terminal rearrangement Biochem. J. 2013, 452, 271-280
10. Saif, G. B.; Al-Khenaizan, S. Netherton syndrome: successful use of topical tacrolimus and pimecrolimus in four siblings Int. J. Dermatol. 2007, 46, 290-294
11. Fontao, L.; Laffitte, E.; Briot, A.; Kaya, G.; Roux-Lombard, P.; Fraitag, S.; Hovnanian, A. A.; Saurat, J. H. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin J. Invest. Dermatol. 2011, 131, 1947-1950
12. Renner, E. D.; Hartl, D.; Rylaarsdam, S.; Young, M. L.; Monaco-Shawver, L.; Kleiner, G.; Markert, M. L.; Stiehm, E. R.; Belohradsky, B. H.; Upton, M. P.; Torgerson, T. R.; Orange, J. S.; Ochs, H. D. Comel-Netherton syndrome defined as primary immunodeficiency J. Allergy Clin. Immunol. 2009, 124, 536-543
13. Vasileiou, Z.; Barlos, K. K.; Gatos, D.; Adermann, K.; Deraison, C.; Barlos, K. Synthesis of the proteinase inhibitor LEKTI domain 6 by the fragment condensation method and regioselective disulfide bond formation Biopolymers 2010, 94, 339-349
14. de Veer, S. J.; Ukolova, S. S.; Munro, C. A.; Swedberg, J. E.; Buckle, A. M.; Harris, J. M. Mechanism-based selection of a potent kallikrein-related peptidase 7 inhibitor from a versatile library based on the sunflower trypsin inhibitor SFTI-1 Biopolymers 2013, 100, 510-518
15. Sotiropoulou, G.; Pampalakis, G. Targeting the kallikrein-related peptidases for drug development Trends Pharmacol. Sci. 2012, 33, 623-634
16. Teixeira, T. S.; Freitas, R. F.; Abrahao, O., Jr.; Devienne, K. F.; de Souza, L. R.; Blaber, S. I.; Blaber, M.; Kondo, M. Y.; Juliano, M. A.; Juliano, L.; Puzer, L. Biological evaluation and docking studies of natural isocoumarins as inhibitors for human kallikrein 5 and 7 Bioorg. Med. Chem. Lett. 2011, 21, 6112-6115
17. Freitas, R. F.; Teixeira, T. S.; Barros, T. G.; Santos, J. A.; Kondo, M. Y.; Juliano, M. A.; Juliano, L.; Blaber, M.; Antunes, O. A.; Abrahao, O., Jr.; Pinheiro, S.; Muri, E. M.; Puzer, L. Isomannide derivatives as new class of inhibitors for human kallikrein 7 Bioorg. Med. Chem. Lett. 2012, 22, 6072-6075
18. Oliveira, J. P.; Freitas, R. F.; Melo, L. S.; Barros, T. G.; Santos, J. A.; Juliano, M. A.; Pinheiro, S.; Blaber, M.; Juliano, L.; Muri, E. M.; Puzer, L. Isomannide-based peptidomimetics as inhibitors for human tissue kallikreins 5 and 7 ACS Med. Chem. Lett. 2014, 5, 128-132
19. Tan, X.; Furio, L.; Reboud-Ravaux, M.; Villoutreix, B. O.; Hovnanian, A.; El Amri, C. 1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases Bioorg. Med. Chem. Lett. 2013, 23, 4547-4551
20. Tan, X.; Bertonati, C.; Qin, L.; Furio, L.; El Amri, C.; Hovnanian, A.; Reboud-Ravaux, M.; Villoutreix, B. O. Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins Eur. J. Med. Chem. 2013, 70, 661-668
21. Quimbar, P.; Malik, U.; Sommerhoff, C. P.; Kaas, Q.; Chan, L. Y.; Huang, Y. H.; Grundhuber, M.; Dunse, K.; Craik, D. J.; Anderson, M. A.; Daly, N. L. High-affinity cyclic peptide matriptase inhibitors J. Biol. Chem. 2013, 288, 13885-13896
22. Glotzbach, B.; Reinwarth, M.; Weber, N.; Fabritz, S.; Tomaszowski, M.; Fittler, H.; Christmann, A.; Avrutina, O.; Kolmar, H. Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1 PLoS One 2013, 8, e76956
23. Fittler, H.; Avrutina, O.; Glotzbach, B.; Empting, M.; Kolmar, H. Combinatorial tuning of peptidic drug candidates: high-affinity matriptase inhibitors through incremental structure-guided optimization Org. Biomol. Chem. 2013, 11, 1848-1857
24. Avrutina, O.; Fittler, H.; Glotzbach, B.; Kolmar, H.; Empting, M. Between two worlds: a comparative study on in vitro and in silico inhibition of trypsin and matriptase by redox-stable SFTI-1 variants at near physiological pH Org. Biomol. Chem. 2013, 10, 7753-7762
25. Enyedy, I. J.; Lee, S. L.; Kuo, A. H.; Dickson, R. B.; Lin, C. Y.; Wang, S. Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase J. Med. Chem. 2001, 44, 1349-1355
26. Doucet, C.; Pochet, L.; Thierry, N.; Pirotte, B.; Delarge, J.; Reboud-Ravaux, M. 6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase J. Med. Chem. 1999, 42, 4161-4171
27. Pochet, L.; Doucet, C.; Schynts, M.; Thierry, N.; Boggetto, N.; Pirotte, B.; Jiang, K. Y.; Masereel, B.; de Tullio, P.; Delarge, J.; Reboud-Ravaux, M. Esters and amides of 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-carboxylic acid as inhibitors of alpha-chymotrypsin: significance of the aromatic nature of the novel ester-type coumarin for strong inhibitory activity J. Med. Chem. 1996, 39, 2579-2585
28. Pochet, L.; Doucet, C.; Dive, G.; Wouters, J.; Masereel, B.; Reboud-Ravaux, M.; Pirotte, B. Coumarinic derivatives as mechanism-based inhibitors of alpha-chymotrypsin and human leukocyte elastase Bioorg. Med. Chem. 2000, 8, 1489-1501
29. Riveiro, M. E.; De Kimpe, N.; Moglioni, A.; Vazquez, R.; Monczor, F.; Shayo, C.; Davio, C. Coumarins: old compounds with novel promising therapeutic perspectives Curr. Med. Chem. 2010, 17, 1325-1338
30. Zhao, H.; Donnelly, A. C.; Kusuma, B. R.; Brandt, G. E.; Brown, D.; Rajewski, R. A.; Vielhauer, G.; Holzbeierlein, J.; Cohen, M. S.; Blagg, B. S. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents J. Med. Chem. 2011, 54, 3839-3853
31. Melliou, E.; Magiatis, P.; Mitaku, S.; Skaltsounis, A. L.; Chinou, E.; Chinou, I. Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity J. Nat. Prod. 2005, 68, 78-82
32. Xie, L.; Takeuchi, Y.; Cosentino, L. M.; Lee, K. H. Anti-AIDS agents. 37. Synthesis and structure-activity relationships of (3′R,4′R)-(+)-cis-khellactone derivatives as novel potent anti-HIV agents J. Med. Chem. 1999, 42, 2662-2672
33. Yu, D.; Suzuki, M.; Xie, L.; Morris-Natschke, S. L.; Lee, K. H. Recent progress in the development of coumarin derivatives as potent anti-HIV agents Med. Res. Rev. 2003, 23, 322-345
34. Xie, L.; Guo, H. F.; Lu, H.; Zhuang, X. M.; Zhang, A. M.; Wu, G.; Ruan, J. X.; Zhou, T.; Yu, D.; Qian, K.; Lee, K. H.; Jiang, S. Development and preclinical studies of broad-spectrum anti-HIV agent (3′R,4′R)-3-cyanomethyl-4-methyl-3′,4′-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK) J. Med. Chem. 2008, 51, 7689-7696
35. Gosselin, F.; Britton, R. A.; Davies, I. W.; Dolman, S. J.; Gauvreau, D.; Hoerrner, R. S.; Hughes, G.; Janey, J.; Lau, S.; Molinaro, C.; Nadeau, C.; OShea, P. D.; Palucki, M.; Sidler, R. A. Practical synthesis of 5-lipoxygenase inhibitor MK-0633 J..Org. Chem. 2010, 75, 4154-4160
36. Kontogiorgis, C. A.; Hadjipavlou-Litina, D. J. Synthesis and antiinflammatory activity of coumarin derivatives J. Med. Chem. 2005, 48, 6400-6408
37. Symeonidis, T.; Chamilos, M.; Hadjipavlou-Litina, D. J.; Kallitsakis, M.; Litinas, K. E. Synthesis of hydroxycoumarins and hydroxybenzo[f]- or [h]coumarins as lipid peroxidation inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 1139-1142
38. Reboud-Ravaux, M.; Wakselman, M. Quinone methides and aza-quinone methides as latent alkylating species in the design of mechanism-based inhibitors of serine proteases and β-lactamases. In The Quinone Methides; Rokita, S. E., Series Ed.; John Wiley & Sons, Inc.: New York, 2009; Vol 1, pp 357-383.
39. Johnson, D. S.; Weerapana, E.; Cravatt, B. F. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors Future. Med. Chem. 2010, 2, 949-964
40. Kalgutkar, A. S.; Dalvie, D. K. Drug discovery for a new generation of covalent drugs Expert Opin. Drug. Discovery 2012, 7, 561-581
41. Singh, J.; Petter, R. C.; Baillie, T. A.; Whitty, A. The resurgence of covalent drugs Nat. Rev. Drug Discovery 2011, 10, 307-317
42. Furio, L.; de Veer, S.; Jaillet, M.; Briot, A.; Robin, A.; Deraison, C.; Hovnanian, A. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome J. Exp. Med. 2014, 211, 499-513
43. Stoermer, R.; Behn, K. Synthese aromatischer Alkohole mit Formaldehyd Ber. Dtsch. Chem. Ges. 1901, 34, 2455-2460
44. Frederick, R.; Charlier, C.; Robert, S.; Wouters, J.; Masereel, B.; Pochet, L. Investigation of mechanism-based thrombin inhibitors: Implications of a highly conserved water molecule for the binding of coumarins within the S pocket Bioorg. Med. Chem. Lett. 2006, 16, 2017-2021
45. Silverman, R. B. Mechanism-based enzyme inactivators Methods. Enzymol. 1995, 249, 240-283
46. Descargues, P.; Deraison, C.; Bonnart, C.; Kreft, M.; Kishibe, M.; Ishida-Yamamoto, A.; Elias, P.; Barrandon, Y.; Zambruno, G.; Sonnenberg, A.; Hovnanian, A. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity Nat. Genet. 2005, 37, 56-65
47. Reboud-Ravaux, M.; Pochet, L.; Doucet, C.; Pirotte, B.; Boggetto, N.; Delarge, J. Coumarin derivatives, methods of preparation and application as medicines. U.S. Patent No 6,355,658 B1, March 2002.
48. Jabin, I.; Revial, G.; Monnier-Benoit, N.; Netchitailo, P. Reaction of cyclohexanone benzylimines with ethylidenemalonate diesters. Diphenyl 2-ethylidenemalonate: a highly electrophilic synthetic equivalent of crotonic esters J. Org. Chem. 2001, 66, 256-261
49. Danek, O. Darstellung von 4-Hydroxycumarin-fluorderivaten Collect. Czech. Chem. Commun. 1964, 29, 654-663
50. Mastumura, Y.; Minoto, D.; Onomura, O. Highly enantioselective introduction of Bis(alkoxycarbonyl)methyl group into the 2-position of piperidine skeleton J. Organomet. Chem. 2007, 692, 654-663
51. Debela, M.; Goettig, P.; Magdolen, V.; Huber, R.; Schechter, N. M.; Bode, W. Structural basis of the zinc inhibition of human tissue kallikrein 5 J. Mol. Biol. 2007, 373, 1017-1031
52. Debela, M.; Hess, P.; Magdolen, V.; Schechter, N. M.; Steiner, T.; Huber, R.; Bode, W.; Goettig, P. Chymotryptic specificity determinants in the 1.0 A structure of the zinc-inhibited human tissue kallikrein 7 Proc. Natl. Acad. Sci. U S A 2007, 104, 16086-16091
53. Friedrich, R.; Fuentes-Prior, P.; Ong, E.; Coombs, G.; Hunter, M.; Oehler, R.; Pierson, D.; Gonzalez, R.; Huber, R.; Bode, W.; Madison, E. L. Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase J. Biol. Chem. 2002, 277, 2160-2168